Harmony Biosciences Holdings, Inc. (HRMY) SEC Filings & Earnings Calls

CEO transition risk; new CEO has limited tenure at company (COO since April 2026).

“Peter Anastasiou appointed CEO effective Jan 1, 2027; previously COO since April 2026.”

Gross margin pressure from new royalties

“Cost of product sold as a percentage of net product revenue was 24.2%... compared to 19.0%... driven by new royalties related to the Novitium License Agreement.” · word for word

Litigation risk from ANDA lawsuit

“In April 2026, we... filed a lawsuit against AET Pharma US, Inc.... alleging that the defendants’ actions... infringe one or more claims of U.S. Patent No. 11,623,920.”

Dependence on single product WAKIX

“Net product revenue is entirely from WAKIX.”

Pipeline dependency on BP-205 and pitolisant GR/HD; regulatory and clinical risks.

“BP-205 IND open; Phase 1b data expected early 2027; Pitolisant GR PDUFA April 2027; Pitolisant HD Phase 3 topline 2027.”

CFO departure creates temporary leadership gap; interim CFO appointed.

“Glenn Reicin... will be stepping down as the Company’s Chief Financial Officer effective as of July 16, 2026 to pursue other career opportunities.”

Increased royalty costs pressuring gross margin

“Cost of product sold as a percentage of net product revenue was 20.7% for the three months ended March 31, 2026, compared to 17.3% for the three months ended March 31, 2025. The increase was driven by new royalties related to the Novitium License Agreement.” · word for word

Event of default on credit agreement

“As of March 31, 2026, the Company had an event of default, which dated back to July 2025, related to a nonfinancial covenant due to a delay in a subsidiary joining the TLA Credit Agreement as a guarantor. On May 4, 2026, the Company entered into a Waiver and Consent Agreement... whereby the event of default was waived.” · word for word

Potential disruption from CFO departure, but orderly transition with experienced replacement.

“CFO departure for other opportunities; new CFO has prior CFO experience at biotech firms.”

Single product dependency

“WAKIX is the sole marketed product; pipeline assets are in clinical stages.”

Clinical development risk

“Clinical development goals were not completed in 2025, impacting bonus payout.”

No material risk signals; executive changes are routine and non-disagreement based.

“Resignation not due to any disagreement; standard severance and non-compete.”

Patent expiration risk

“One U.S. patent, No. 8,207,197 has claims directed to the polymorph... which is expected to expire in in March 2030.” · word for word

Single product dependency

“Net product revenue increased by $153.7 million, or 21.5% for the year ended December 31, 2025, compared to the same period in 2024. (All revenue from WAKIX)” · word for word

ANDA litigation risk

“General and administrative expenses increased by $42.2 million, or 38.2%... primarily due to a $39.0 million increase in legal and professional fees, primarily associated with patent lawsuits and settlements.” · word for word

Pipeline execution risk

“The RECONNECT study did not meet the primary endpoint of improvement in social avoidance primarily due to a higher-than-expected placebo response rate.” · word for word

Dependence on single product WAKIX for revenue.

“All revenue from WAKIX; pipeline diversification still in clinical stages.”

Clinical trial risk for pipeline assets.

“Phase 3 trials ongoing; topline data readouts in 2026 and 2027.”

Pipeline execution risk for late-stage programs.

“Late-stage pipeline advances but clinical trial outcomes uncertain.”

Concentration risk on WAKIX single product.

“Revenue entirely from WAKIX franchise.”

Pipeline failure risk

“ZYN002 Phase 3 RECONNECT study did not meet primary endpoint; FXS program paused.”

Dependence on single product WAKIX

“All net product revenue is from WAKIX; pipeline candidates are in early to mid-stage development.”

Royalty rate increase pressure

“Cost of product sales as a percentage of revenue increased due to triggering a higher royalty tier under the 2017 LCA.” · word for word